Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss how to get the shot registered locally as fast as possible in the country.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Researchers Open New Leads in Anti-HIV Drug Development, Using a Compound Found in Nature Mar. 8, 2024 — A team of researchers has successfully modified a naturally occurring chemical compound ...

The National Agency for the Control of AIDS (NACA), Global Network of Young People Living with HIV (Y+ Global), and the Joint ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...

Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...

LGBTQ group says Uganda has lost potentially up to $1.6 billion in GDP following the passage of a law criminalizing ...

(At the former location) we only offered one, and it was inside,” Alexa Bottoms, HOPE’s program coordinator, said of the ...

They were protesting the denial of day care services to an HIV-positive mother in Madison ... Many look back on protests ...